Ignite Creation Date:
2025-12-24 @ 3:19 PM
Ignite Modification Date:
2026-02-03 @ 5:17 AM
Study NCT ID:
NCT01987492
Status:
COMPLETED
Last Update Posted:
2017-05-22
First Post:
2013-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Bulgaria']}, 'conditionBrowseModule': {'meshes': [{'id': 'D001249', 'term': 'Asthma'}], 'ancestors': [{'id': 'D001982', 'term': 'Bronchial Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012130', 'term': 'Respiratory Hypersensitivity'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C561806', 'term': 'lebrikizumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 230}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-02-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-05', 'completionDateStruct': {'date': '2016-12-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-05-19', 'studyFirstSubmitDate': '2013-11-12', 'studyFirstSubmitQcDate': '2013-11-12', 'lastUpdatePostDateStruct': {'date': '2017-05-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-11-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-12-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Relative Change From Baseline in Daily OCS Dose at Week 44', 'timeFrame': 'Baseline, Week 44'}], 'secondaryOutcomes': [{'measure': 'Absolute Change From Baseline in Daily OCS Dose at Week 44', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Relative Change From Week 12 in Average OCS Dose at Week 44', 'timeFrame': 'Week 12, Week 44'}, {'measure': 'Percentage of Participants Achieving at Least a 50 percent (%) Reduction in Their Daily OCS Dose at Week 44 Relative to Baseline', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Percentage of Participants Discontinuing OCS Therapy or Having Achieved an Adrenal Maintenance Dose at Week 44', 'timeFrame': 'Week 44', 'description': 'Percentage of participants discontinuing OCS therapy or having achieved adrenal maintenance dose (cortisol level less than or equal to 100 nanomoles per liter) will be reported.'}, {'measure': 'Percentage of Participants With Asthma Exacerbations', 'timeFrame': 'Baseline up to Week 44', 'description': 'An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, or nocturnal awakenings due to these symptoms) that lead to treatment with systemic corticosteroids greater than or equal to (\\>/=) 30 milligrams (mg) or 0.5 mg per kilogram (kg) for \\>/=3 consecutive days or to hospitalization.'}, {'measure': 'Percentage of Participants With Adverse Events', 'timeFrame': 'Baseline up to 24 weeks after last dose administration (up to a minimum of approximately 2 years)'}, {'measure': 'Percentage of Participants With Anti-therapeutic Antibodies (ATAs) Against Lebrikizumab', 'timeFrame': 'Predose (0 hours) at Weeks 0, 4, 12, 24, 36, 44, 52, 64, and 76, at early discontinuation (up to a minimum of approximately 2 years), and at 24 weeks after last dose administration (up to a minimum of approximately 2 years)'}, {'measure': 'Minimum Observed Serum Lebrikizumab Concentration (Cmin)', 'timeFrame': 'Predose (0 hours) at Weeks 4, 12, 24, 36, and 44'}]}, 'conditionsModule': {'conditions': ['Asthma']}, 'descriptionModule': {'briefSummary': 'This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of OCS, among those with severe corticosteroid-dependent asthma. Prednisone/prednisolone will be the OCS therapy prescribed. Participants will be randomized to receive lebrikizumab or matching placebo for 44 weeks in a double-blind, placebo-controlled (DBPC) period. Those who complete the 44-week period may continue into a 32-week active treatment extension (ATE) period, during which all participants will receive lebrikizumab treatment. Following completion of the ATE period, participants who have both tolerated and derived benefit from treatment with lebrikizumab may continue their lebrikizumab treatment into a long-term extension (LTE) period. Participants will transition to 24 weeks of safety follow-up upon discontinuation of study drug.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Severe asthma despite intensive follow-up by an asthma specialist for \\>/=6 months prior to Visit 1\n* Baseline forced expiratory volume in 1 second (FEV1) \\>/=40% of predicted prior to randomization\n* Receiving high doses of inhaled glucocorticosteroids at a total daily dose of \\>/=1500 micrograms (mcg) beclomethasone dipropionate or equivalent and long-acting beta-adrenoceptor agonist (LABA), with or without an additional controller, for at least 3 months prior to Visit 1\n* Chronic treatment with maintenance OCS for \\>/=6 months prior to Visit 1\n* Assessment to ensure diagnosis of refractory asthma and OCS dependence on minimal effective or maximum tolerated dose prior to Visit 1 with compliance\n\nExclusion Criteria:\n\n* History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection\n* Asthma exacerbation within 28 days prior to Visit 1 or during screening (prior to Visit 3)\n* For adults: Active tuberculosis requiring treatment within the 12 months prior to Visit 1\n* For adolescents: History of active tuberculosis requiring treatment\n* Evidence of acute or chronic hepatitis or known liver cirrhosis\n* Known current malignancy or current evaluation for a potential malignancy\n* History of interstitial lung disease, chronic obstructive pulmonary disease, or other clinically significant lung disease other than asthma\n* Infection requiring hospital admission or requiring treatment with intravenous (IV) or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening\n* Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening\n* Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening\n* Current smoker or former smoker with a smoking history of more than 15 pack-years\n* Current use of an immunomodulatory/ immunosuppressive therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to Visit 1\n* Use of a licensed or investigational monoclonal antibody other than anti-interleukin (IL)-13 or anti-IL-4/IL-13, including but not limited to, omalizumab, anti-IL-5, or anti-IL-17, within 6 months or 5 drug half-lives (whichever is longer) prior to Visit 1\n* Receipt of a live attenuated vaccine within the 4 weeks prior to Visit 1 during screening or anticipation of receipt of a live attenuated vaccine throughout the study'}, 'identificationModule': {'nctId': 'NCT01987492', 'briefTitle': 'A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Oral Corticosteroid-Sparing Effect of Lebrikizumab in Patients With Severe Corticosteroid Dependent Asthma', 'orgStudyIdInfo': {'id': 'WB28182'}, 'secondaryIdInfos': [{'id': '2012-000190-24', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Lebrikizumab High Dose', 'description': 'Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.', 'interventionNames': ['Drug: Lebrikizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Lebrikizumab Low Dose', 'description': 'Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.', 'interventionNames': ['Drug: Lebrikizumab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.', 'interventionNames': ['Drug: Lebrikizumab', 'Drug: Placebo']}], 'interventions': [{'name': 'Lebrikizumab', 'type': 'DRUG', 'otherNames': ['RO5490255'], 'description': 'Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.', 'armGroupLabels': ['Lebrikizumab High Dose', 'Lebrikizumab Low Dose', 'Placebo']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93301', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'Kern Allergy Med Clinic, Inc.', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '90808', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Allergy & Asthma Care Center of Southern California', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '33135', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'South Florida Research Center, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '31707', 'city': 'Albany', 'state': 'Georgia', 'country': 'United States', 'facility': 'Georgia Pollens', 'geoPoint': {'lat': 31.57851, 'lon': -84.15574}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mount Sinai Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '74136', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Allergy & Immunology', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '77008', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Pioneer Research Solutions', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75069', 'city': 'McKinney', 'state': 'Texas', 'country': 'United States', 'facility': 'Metroplex Pulmonology & Sleep Center', 'geoPoint': {'lat': 33.19762, 'lon': -96.61527}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Pulmonary Consultants PLLC', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '4102', 'city': 'Brisbane', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine', 'geoPoint': {'lat': -27.46794, 'lon': 153.02809}}, {'zip': '3168', 'city': 'Clayton', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Monash Medical Centre; Respiratory and Sleep Medicine', 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'zip': '6009', 'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Institute for Respiratory Health Inc', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': '1070', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Clin Univ de Bxl Hôpital Erasme', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '3600', 'city': 'Genk', 'country': 'Belgium', 'facility': 'Longartsenpraktijk', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'zip': '9000', 'city': 'Ghent', 'country': 'Belgium', 'facility': 'UZ Gent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': 'M5T 3A9', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Inspiration Research Limited', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '618 00', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Hornmed', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '460 63', 'city': 'Liberec', 'country': 'Czechia', 'facility': 'Nemocnice Liberec; KNL a.s. - TRN', 'geoPoint': {'lat': 50.76711, 'lon': 15.05619}}, {'zip': '741-01', 'city': 'Nový Jičín', 'country': 'Czechia', 'facility': 'Nemocnice Nový Jičín', 'geoPoint': {'lat': 49.59438, 'lon': 18.01028}}, {'zip': '337 22', 'city': 'Rokycany', 'country': 'Czechia', 'facility': 'Rokycanska nemocnice', 'geoPoint': {'lat': 49.7427, 'lon': 13.59459}}, {'zip': '2900', 'city': 'Hellerup', 'country': 'Denmark', 'facility': 'Gentofte Hospital, Klinik for Allergi', 'geoPoint': {'lat': 55.73204, 'lon': 12.57093}}, {'zip': '38043', 'city': 'Grenoble', 'country': 'France', 'facility': 'CHU de Grenoble - Hôpital André Michallon', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'zip': '94275', 'city': 'Le Kremlin-Bicêtre', 'country': 'France', 'facility': 'CH de Bicetre; Pneumologie', 'geoPoint': {'lat': 48.81471, 'lon': 2.36073}}, {'zip': '69004', 'city': 'Lyon', 'country': 'France', 'facility': 'Hôpital de La Croix Rousse', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'Hôpital Arnaud de Villeneuve', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'CHU Nantes - Hôpital Laennec; Service de Pneumologie', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '06001', 'city': 'Nice', 'country': 'France', 'facility': 'CHU de Nice', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '75877', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Bichat Claude Bernard ; Service de Pneumologie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '33604', 'city': 'Pessac', 'country': 'France', 'facility': 'CHU de Haut Leveque', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'zip': '67091', 'city': 'Strabourg', 'country': 'France', 'facility': 'Nouvel Hôpital Civil; Pôle de Pathologie Thoracique'}, {'zip': '44100', 'city': 'Guadalajara', 'country': 'Mexico', 'facility': 'Instituto Jalisciense de Investigacion Clinica S.A. de C.V.', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '44130', 'city': 'Guadalajara', 'country': 'Mexico', 'facility': 'Centro Investigacion Medico Biologica y Terapia Avanzada', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '76800', 'city': 'Querétaro', 'country': 'Mexico', 'facility': 'Centro Integral Médico SJR SC', 'geoPoint': {'lat': 15.83752, 'lon': -92.75774}}, {'zip': '1105 AZ', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Academisch Medisch Centrum; Afdeling Longziekten, F5-258', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '2134 TM', 'city': 'Hoofddorp', 'country': 'Netherlands', 'facility': 'Spaarne Ziekenhuis Hoofddorp; Long Geneeskunde', 'geoPoint': {'lat': 52.3025, 'lon': 4.68889}}, {'zip': '3435 CM', 'city': 'Nieuwegein', 'country': 'Netherlands', 'facility': 'Antonius Ziekenhuis; Dept of Lung Diseases', 'geoPoint': {'lat': 52.02917, 'lon': 5.08056}}, {'zip': '1051', 'city': 'Auckland', 'country': 'New Zealand', 'facility': 'NZ Respiratory & Sleep Institute', 'geoPoint': {'lat': -36.84853, 'lon': 174.76349}}, {'city': 'Dunedin', 'country': 'New Zealand', 'facility': 'Dunedin Hospital', 'geoPoint': {'lat': -45.87416, 'lon': 170.50361}}, {'zip': '3143', 'city': 'Tauranga', 'country': 'New Zealand', 'facility': 'Clinical Trials Unit, Bay of Plenty District Health Board', 'geoPoint': {'lat': -37.68611, 'lon': 176.16667}}, {'city': 'Wellington', 'country': 'New Zealand', 'facility': 'Medical Research Inst. of New Zealand; Respiratory', 'geoPoint': {'lat': -41.28664, 'lon': 174.77557}}, {'zip': '31-024', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Specjalistyczny Osrodek Alergologiczno-Internistyczny ALL-MED', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '31-624', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Malopolskie Centrum Alergologii', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-153', 'city': 'Lodz', 'country': 'Poland', 'facility': 'SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '63-400', 'city': 'Ostrów Wielkopolski', 'country': 'Poland', 'facility': 'Specjalistyczna Poradnia Pulmonologiczna', 'geoPoint': {'lat': 51.65501, 'lon': 17.80686}}, {'zip': '41-707', 'city': 'Ruda Śląska', 'country': 'Poland', 'facility': 'Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA Wladyslaw Pierzchala', 'geoPoint': {'lat': 50.2584, 'lon': 18.85632}}, {'zip': '02-507', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Klinika Chorób Wewnetrznych i Alergologii MSW', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50-220', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'EMC Instytut Medyczny SA; Przychodnia przy ulicy Łowieckiej', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '00725', 'city': 'Caguas', 'country': 'Puerto Rico', 'facility': 'San Juan Bautista School of Medicine-Clinical Research Unit', 'geoPoint': {'lat': 18.23412, 'lon': -66.0485}}, {'zip': '00739', 'city': 'Cidra', 'country': 'Puerto Rico', 'facility': 'Advanced Medical Concepts, PSC', 'geoPoint': {'lat': 18.17579, 'lon': -66.16128}}, {'zip': '934 01', 'city': 'Levice', 'country': 'Slovakia', 'facility': 'ZAPA JJ Sro', 'geoPoint': {'lat': 48.21563, 'lon': 18.60705}}, {'zip': '052 01', 'city': 'Spišská Nová Ves', 'country': 'Slovakia', 'facility': 'Plucna ambulancia', 'geoPoint': {'lat': 48.94464, 'lon': 20.56153}}, {'zip': '4204', 'city': 'Golnik', 'country': 'Slovenia', 'facility': 'University Clinic of Pulmonary and Allergic Diseases Golnik', 'geoPoint': {'lat': 46.33333, 'lon': 14.33333}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'state': 'La Coruña', 'country': 'Spain', 'facility': 'Complejo Hospitalario Universitario de Santiago; Servicio de Neumología', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '08025', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital de la Santa Creu; i Sant Pau', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clinic de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '37007', 'city': 'Salamanca', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario de Salamanca; Servicio de Neumologia', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'zip': '46017', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Hospital Universitario Doctor Peset', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': 'BT9 7AB', 'city': 'Belfast', 'country': 'United Kingdom', 'facility': 'Belfast City Hospital; Respiratory Department', 'geoPoint': {'lat': 54.59682, 'lon': -5.92541}}, {'zip': 'B9 5SS', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Heartlands Hospital; Respiratory Department', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'G12 0YN', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Gartnavel General Hospital; Respiratory Department', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'G31 2ER', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'New Lister Buliding, Level 1; Clinical Research Facility', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'G51 4TF', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Royal Hospital For Children', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'SO16 6YD', 'city': 'Hampshire', 'country': 'United Kingdom', 'facility': 'Southampton General Hospital; Respiratory Department'}, {'zip': 'LE1 5WW', 'city': 'Leicester', 'country': 'United Kingdom', 'facility': 'Leicester Royal Infirmary NHS Trust', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'zip': 'LE3 9QP', 'city': 'Leicester', 'country': 'United Kingdom', 'facility': 'Glenfield Hospital; Respiratory -Allergy Unit', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'zip': 'EC1A 7BE', 'city': 'London', 'country': 'United Kingdom', 'facility': "St Bartholomew's Hospital (Barts); Respiratory Department", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW3 6NP', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Royal Brompton Hospital; Respiratory Department', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M23 9LT', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Wythenshawe Hospital; North West Lung Research Centre', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'NE7 7DN', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'facility': 'Freeman Hospital; Respiratory Department', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'PL6 8DH', 'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Derriford Hospital; The Lind Research Department', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'S10 2JF', 'city': 'Sheffield', 'country': 'United Kingdom', 'facility': 'Sheffield Clinical Research Facility; National Institute for Health Research', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}